AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01138943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthodont
Description: 15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse
Study NCT01138943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soludent
Description: 15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse
Study NCT02788162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
Study NCT00088205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 500 milligrams (mg), oral, daily, up to six 28-day cycles
Study NCT00988351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: continuous positive airway pressure determined by polysomnography titration
Study NCT00988351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto-adjusting positive airway pressure treatment
Description: Pressure range 4-18 centimeters of water (cm H2O)
Study NCT02587689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MUC1 CAR T Cells
Study NCT01654237 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: questionnaires
Description: 185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
Study NCT02430922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iVolution nitinol stent
Study NCT05575115 — intervention group
Intervention type: BEHAVIORAL
Intervention: Peer Comparison
Description: Peer comparison was an email-based intervention. Clinicians were ranked from highest to lowest inappropriate prescribing rate within each region using EHR data. Clinicians with the lowest inappropriate prescribing rates (the top-performing decile) were told via monthly email they were Top Performers. The remaining clinicians were told that they were Not a Top Performer in an email that included the number and proportion of antibiotic prescriptions they wrote for antibiotic-inappropriate acute respiratory tract infections, compared with the proportion written by top performers.
Study NCT03806946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalography
Description: diagnosis epileptic discharge
Study NCT01661257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Study NCT01850615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Administrated subcutaneously (s.c., under the skin) at each main meal.
Study NCT01850615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin
Description: Administrated subcutaneously (s.c., under the skin) once daily.
Study NCT01850615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basal insulin
Description: Administrated subcutaneously (s.c., under the skin) once daily.
Study NCT02209506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets
Study NCT02209506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126 Matched Placebo
Description: MLN3126 placebo-matching tablets
Study NCT05886361 — intervention group
Intervention type: OTHER
Intervention: No intervention involved
Description: No intervention involved
Study NCT01968941 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Study NCT01968941 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiotherapy (CRT)
Study NCT03578679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Oral Product
Description: treatment of pediculosis (head lice)
Study NCT00728429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: 24 week program of exercise
Study NCT01287104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) Cell Infusion
Description: Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
Study NCT01287104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Transplant Day 0: >4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) >5000/microliters x2
Study NCT03835663 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
Description: Standard upper GI endoscopy with biopsies
Study NCT04319848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TE-EK treatment group
Description: Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
Study NCT00098787 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00098787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00098787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00098787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00098787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03806946 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: psychometric scales to diagnosis psychiatric disorders
Description: to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.
Study NCT03141671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
Study NCT03141671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study NCT03600480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous \[s.c.\], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.
Study NCT03600480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.
Study NCT03600480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.
Study NCT03806946 — intervention group
Intervention type: OTHER
Intervention: psychometric scales for assesment socioeconomic and behaviour problems
Description: to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
Study NCT01435941 — intervention group
Intervention type: DRUG
Intervention: Non-steroidal anti-inflammatory drug (NSAID)
Description: Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
Study NCT01435941 — intervention group
Intervention type: DRUG
Intervention: Triptan
Description: Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
Study NCT03846479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: for up to 56 days
Study NCT02747082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retreatment of root-filled teeth with infection
Description: Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
Study NCT02689622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: research of disease-related factors
Description: included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
Study NCT01361711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given SC
Study NCT01361711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Given IV
Study NCT01361711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT03253640 — intervention group
Intervention type: OTHER
Intervention: Exposure
Description: Healthcare associated infection (HAI)
Study NCT03600480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (NNC0174-0833)
Description: Participants will receive once weekly injections of NNC0174-0833 matched placebo.
Study NCT01885052 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QuitTXT Study
Description: Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
Study NCT01885052 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low Contact
Study NCT04013919 — intervention group
Intervention type: DRUG
Intervention: Multiple Daily Injections of Insulin
Description: Basal/ Bolus insulin injections
Study NCT04013919 — intervention group
Intervention type: DRUG
Intervention: Single insulin injections
Description: Basal insulin injections only
Study NCT00328926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luveris® 75 IU
Description: Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol \[E2\] levels). Total duration will be of 3 treatment cycles.
Study NCT00328926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Luveris® 25 IU
Description: Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Study NCT00328926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Study NCT00328926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Study NCT00328926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Study NCT00328926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Study NCT00328926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
Study NCT03183037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
Study NCT02689622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: research of comorbidities
Description: HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
Study NCT02689622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical performance
Description: Activities of Daily Living and physical performance
Study NCT01113749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding Options in Dementia Decision Aid
Description: Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
Study NCT04244812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm.
Study NCT04244812 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laser doppler flowmetry
Description: Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
Study NCT04244812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser doppler flowmetry
Description: Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
Study NCT02205554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnitram
Description: Nine 20 mg doses administered every 6 hours
Study NCT02205554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Nine 50 mg doses administered every 6 hours.
Study NCT02205554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Nine doses administered every 6 hours.
Study NCT01330017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl
Description: 10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
Study NCT01330017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
Study NCT01330017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
Study NCT01330017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
Study NCT01330017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: 10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
Study NCT02757638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
Study NCT03700541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine intravenous
Study NCT03700541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramid
Description: Piritramid intravenous
Study NCT04615455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCs
Description: ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.
Study NCT04615455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cryostor CS10
Description: CryoStor® CS10 freeze medium
Study NCT00796887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Niacin
Description: 500mg tablet once daily
Study NCT00796887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Niacin
Description: 1000mg tablet once daily
Study NCT00796887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study NCT02363023 — intervention group
Intervention type: PROCEDURE
Intervention: Collect tracheal and pulmonary secretions
Description: Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
Study NCT03841578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy
Description: 25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
Study NCT04300959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin
Description: Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks.
Study NCT04300959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Plus(+)Cisplatin
Description: Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks.
Study NCT02601807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiPatch (active)
Description: Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
Study NCT02601807 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ActiPatch (placebo)
Description: Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
Study NCT04363398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Follow-up
Description: Trained research staff members will provide weekly support to coaches on the NMT warm-up.
Study NCT04363398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-up
Description: Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
Study NCT03331471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar recruitment maneuver
Description: applying alveolar recruitment maneuver using the anesthesia machine
Study NCT03331471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional ventilation
Description: conventional ventilation using the anesthesia machine